Jean-Francois Sarrazin
Overview
Explore the profile of Jean-Francois Sarrazin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sapp J, Tang A, Parkash R, Stevenson W, Healey J, Gula L, et al.
N Engl J Med
. 2024 Nov;
392(8):737-747.
PMID: 39555820
Background: Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter...
2.
Domain G, Blais-Lecours P, Strube C, Dognin N, Chateauvert N, Savard N, et al.
CJC Open
. 2024 Nov;
6(9):1035-1041.
PMID: 39525818
Background: Ozanimod is a novel immune modulator that could be useful in viral pulmonary infections by reducing lung inflammation. It is an S1P receptor ligand known to induce bradycardia and...
3.
Shurrab M, Janmohamed A, Ayala-Paredes F, Sturmer M, Toal S, Sarrazin J, et al.
Heart Rhythm O2
. 2024 Nov;
5(9):668-671.
PMID: 39493910
No abstract available.
4.
Joza J, Nair G, Birnie D, Nery P, Redpath C, Sarrazin J, et al.
J Cardiovasc Electrophysiol
. 2023 Nov;
35(1):136-145.
PMID: 37990448
Introduction: Pulmonary vein isolations (PVI) are being performed using a high-power, short-duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of an...
5.
Lellouche F, Blais-Lecours P, Maltais F, Sarrazin J, Rola P, Nguyen T, et al.
Chest
. 2023 Oct;
165(4):810-819.
PMID: 37898184
Background: Sphingosine-1-phosphate receptor ligands (SRLs) dampen immunopathologic damages in models of viral pneumonia. Research Question: Is it feasible to administer an SRL therapy, here ozanimod (OZA), to acutely ill patients...
6.
Steinberg C, Gaudreault N, Papadakis A, Henry C, Champagne J, Philippon F, et al.
Europace
. 2023 Jun;
25(6).
PMID: 37314195
Aims: Risk stratification for sudden cardiac death in patients with Brugada syndrome remains a major challenge. Contemporary risk prediction models have only modest predictive value. The aim of this study...
7.
Domain G, Strube C, Jacques F, Marzouk M, Dumont E, Villeneuve J, et al.
Pacing Clin Electrophysiol
. 2023 May;
46(7):639-644.
PMID: 37196145
Introduction: Superior vena cava (SVC) tear is the most lethal complication during transvenous lead extraction (TLE) with a mortality rate as high as 50%. Treatment involves aggressive attempts to maintain...
8.
Gold M, Ellenbogen K, Leclercq C, Lowy J, Rials S, Shoda M, et al.
Circ Arrhythm Electrophysiol
. 2023 May;
16(6):e011714.
PMID: 37183700
Background: The role of atrioventricular optimization (AVO) to improve cardiac resynchronization therapy outcomes remains controversial. Previous post hoc analyses of a multicenter trial showed that measures of electrical dyssynchrony (right...
9.
Nair G, Birnie D, Nery P, Redpath C, Sarrazin J, Roux J, et al.
JAMA Cardiol
. 2023 Mar;
8(5):475-483.
PMID: 36947030
Importance: Recurrent atrial fibrillation (AF) commonly occurs after catheter ablation and is associated with patient morbidity and health care costs. Objective: To evaluate the superiority of an augmented double wide-area...
10.
Gaudreault N, Ruel L, Henry C, Schleit J, Lague P, Champagne J, et al.
Am J Med Genet A
. 2023 Mar;
191(6):1508-1517.
PMID: 36864778
Variants of filamin C (FLNC) have been identified as rare genetic substrate for hypertrophic cardiomyopathy (HCM). Data on the clinical course of FLNC-related HCM are conflicting with some studies suggesting...